BIOCON / Q2-FY26 / claim-ledger

Audit the questions that mattered.

Biocon · Analyst questions, management answers, and the quality of the response where the ledger is available.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

PositiveQ2-FY26 · 2025-10-31Back to quarter ↗

Questions audited

Answered directly

71%

Numeric claims

Consistency

—

Question ledger

What was answered, and how?

Tushar Manudhane · Motilal Oswal

partial

Traction expected from insulin aspart launch as only interchangeable player.

We are seeing a very strong traction for our insulin products, not just in the U.S., but globally. We will, and we have already launched aspart in a very responsible manner... You will then get a full calendar 2026 opportunity.

Tushar Manudhane · Motilal Oswal

direct

R&D spend guidance for biosimilars as % of revenue.

We've said, Tushar, that we would be in that 7%-9% of revenues for R&D. And we continue to be in that range even now, and on a full year basis, you will see us in that 7%-9% range.

Tushar Manudhane · Motilal Oswal

direct

Gross margins and R&D spend for generics business.

R&D spends, again, last quarter was at 9% of generics revenue, and I expect it to be in a similar trajectory of 8%-10% of revenues. As far as the gross margins are concerned, we are looking at mid-40s%.

Harith Ahamed · Avendus

direct

Impact of FDA guidance on lowering comparative efficacy trials on R&D spend.

It certainly lowers the cost to development, and it certainly shortens the time to bring products to market... it increases the focus and the burden on CMC development and facility GMP clearance for biologics.

Harith Ahamed · Avendus

evasive

Expectation of increased competitive intensity from new players due to FDA guidance.

established players like Biocon, Biocon Biologics will have a clear advantage of bringing more products to the market. So we don't necessarily see this as a competitive threat, but we see this as a great opportunity.

Harith Ahamed · Avendus

direct

Drivers of improved performance in generics business.

the main uptake in the margin is because of the GLP-1 Liraglutide launch in the European market. And we, of course, have other products as well, which contributed to the revenue growth and the profit growth.

Harith Ahamed · Avendus

direct

Timing of interest cost reduction from debt repayment.

I think Q3 will reflect the quarter, and then Q4 should reflect the Edelweiss.

Sidharth Negandhi · CWC

partial

Impact of formulary exclusions on aspart sales and Biocon's Keytruda biosimilar plans.

Shreehas: 'we believe we are in a position of strength at this point in time on these products.' Matt: 'we don't see any limitations because of the channels... customers are continuing to be very bullish on aspart from Biocon.'

Love Sharma · JPMorgan

direct

Current outstanding structured debt as of September quarter.

the only instrument which is outstanding as of 30th September is the Edelweiss instrument. Goldman Sachs exit happened on 30th June, and the quarter exit happened on 1st of October. And we have agreed with Edelweiss to exit on or before 31st January.

Surya Patra · PhillipCapital

direct

Split between formulation and API in generics and margin profile.

almost 60% of the business continues to come from API, and 40% is coming from formulation. And then over the last couple of quarters, formulation is what's driving the growth.

Surya Patra · PhillipCapital

evasive

Device and filling capacity for GLP-1 products.

capacity will not be a constraint on the formulation side or the device side. We have multiple facilities... we have just commissioned a new injectable facility, which is, again, dedicated or focused on GLP-1s.

Surya Patra · PhillipCapital

partial

Market share for Yesintek and aspart potential vs Semglee.

over 70% of the commercial formularies listing the product... it's hard to talk about what market shares would look like, but the formulary coverage and the fact that we see uptick of the product indicates that Yesintek has an early lead.